Cargando…
Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key?
Immunotherapy treatment strategies have proven effective in a limited portion of patients, where identifying responders from non-responders to treatment remains a challenge. While some indications can be drawn from invasive biopsies, we need more accessible methods for predicting response and better...
Autores principales: | Flaherty, Katie R, Kucykowicz, Stephanie, Schroth, Johannes, Traves, Will, Mincham, Kyle T, Finney, George E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676196/ https://www.ncbi.nlm.nih.gov/pubmed/38020310 http://dx.doi.org/10.1093/immadv/ltad026 |
Ejemplares similares
-
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
por: Morrison, Carl, et al.
Publicado: (2018) -
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
por: Ziogas, Dimitrios C., et al.
Publicado: (2023) -
TIM-3: a tumor-associated antigen beyond checkpoint inhibition?
por: Barth, Stefan, et al.
Publicado: (2022) -
Commentary: Moving beyond phenotypic diagnosis
por: Stansfield, William E.
Publicado: (2020) -
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
por: Ascierto, Paolo A., et al.
Publicado: (2017)